- Conditions
- Migraine Headache
- Interventions
- Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
- Drug · Behavioral
- Lead sponsor
- Ohio University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 2
- States / cities
- Athens, Ohio • Westerville, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 988
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypercholesterolemia
- Interventions
- AZD8233
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy
- Interventions
- INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days, Victrelis 800 mg TID with INX-08189 50 mg QD, Placebo with Victrelis 800 mg, Cohort 2: Victrelis 800 mg with Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Dilated Cardiomyopathy, Lamin A/C Gene Mutation
- Interventions
- ARRY-371797 (PF-07265803), Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more
- Conditions
- Steatohepatitis
- Interventions
- AZD7503
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Chandler, Arizona • Montclair, California • Hialeah, Florida + 5 more
- Conditions
- Heart Failure, Healthy Volunteer
- Interventions
- AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 8
- States / cities
- Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more
- Conditions
- Elevated High-sensitivity C-Reactive Protein (hsCRP)
- Interventions
- Rosuvastatin, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 17,802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 431
- States / cities
- Birmingham, Alabama • Calera, Alabama • Columbiana, Alabama + 428 more
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Ezetimibe, Placebo to Evolocumab
- Biological · Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Tivantinib, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 17 more
- Conditions
- Obesity and Overweight
- Interventions
- MET233, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®
- Drug · Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- JKB-121: 5 mg twice daily, JKB-121: 10 mg twice daily, Placebo
- Drug
- Lead sponsor
- Manal Abdelmalek
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Dothan, Alabama • Chicago, Illinois • Las Vegas, Nevada + 5 more
- Conditions
- Hepatitis C
- Interventions
- GSK2485852 70 mg, GSK2485852 420 mg, placebo, GSK2485852 630 mg, GSK2485852 70 mg + Ritonavir 100mg, GSK2485852 210 mg +Ritonavir 100mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 5
- States / cities
- Anaheim, California • Orlando, Florida • Lenexa, Kansas + 2 more
- Conditions
- Asthma
- Interventions
- Vitamins A, E, C & Selenium, Placebo
- Dietary Supplement
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- COVID-19
- Interventions
- Clazakizumab, Placebo
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, Canagliflozin 300mg/Placebo, Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 5
- States / cities
- Chula Vista, California • Miramar, Florida • Cincinnati, Ohio + 2 more
- Conditions
- Immunodeficiency Virus Type 1, Human
- Interventions
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC, D/C/F/TAF FDC - Matching Placebo, FTC/TDF FDC Matching Placebo, DRV/COBI FDC Matching Placebo
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 725 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo for dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 833 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 36
- States / cities
- Little Rock, Arkansas • Encino, California • La Mesa, California + 33 more
- Conditions
- TQT Study
- Interventions
- Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo, Moxifloxacin 400mg, Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr), Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
- Drug · Other
- Lead sponsor
- Spero Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Interventions
- Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device
- Combination Product
- Lead sponsor
- Bellerophon Pulse Technologies
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 43
- States / cities
- Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more
- Conditions
- Endometriosis, CBD, Pelvic Pain
- Interventions
- Cannabidiol (CBD) Extract, Norethindrone Acetate, Placebo
- Drug · Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Secondary Osteoporosis, Spinal Cord Injury
- Interventions
- Denosumab (Prolia), Placebo (normal saline)
- Drug · Other
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- West Orange, New Jersey • The Bronx, New York
- Conditions
- Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus
- Interventions
- Hemopfin+Green Light, Vehicle+Green Light
- Drug · Device
- Lead sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Irvine, California • San Diego, California • Miami, Florida + 2 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Placebo, SCY-635
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- San Francisco, California • Richmond, Virginia